vimarsana.com

Page 8 - Nccn Guidelines News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Inpatient to Outpatient: Myelofibrosis Care

Pharmacists discuss challenges in transitioning myelofibrosis patients between inpatient and outpatient care settings, emphasizing medication reconciliation and seamless inter-team communication.

Emerging Therapies and Momelotinib Impact

James Davis, PharmD, BCOP, discusses momelotinib usage and highlights emerging therapies revolutionizing myelofibrosis treatment paradigms.

Impact and Adoption of Momelotinib in Myelofibrosis

Pharmacists analyze momelotinib's role in treating anemia in myelofibrosis, exploring its place in practice and impact on patient care amidst emerging therapies.

Investigational Avenues in Uncommon EGFR Mutations: NSCLC Treatment Insight

Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.